The role of mitochondrial/metabolic axis in development of tamoxifen resistance in breast cancer

[1]  A. Jalil,et al.  Metabolic reprogramming by miRNAs in the tumor microenvironment: Focused on immunometabolism , 2022, Frontiers in Oncology.

[2]  E. El-demerdash,et al.  Metabolic/hypoxial axis predicts tamoxifen resistance in breast cancer , 2022, Scientific Reports.

[3]  C. Taylor,et al.  The effect of HIF on metabolism and immunity , 2022, Nature Reviews Nephrology.

[4]  Q. Su,et al.  HIF-1α-regulated lncRNA-TUG1 promotes mitochondrial dysfunction and pyroptosis by directly binding to FUS in myocardial infarction , 2022, Cell death discovery.

[5]  Li-gang Wu,et al.  The Role of Non-Coding RNAs in Breast Cancer Drug Resistance , 2021, Frontiers in Oncology.

[6]  M. Hedayati,et al.  Tamoxifen triggers apoptosis of papillary thyroid cancer cells by two different mechanisms , 2021 .

[7]  Mina Wang,et al.  PPAR-α Modulators as Current and Potential Cancer Treatments , 2021, Frontiers in Oncology.

[8]  XiaoPeng Wang,et al.  Identification of key genes involved in tamoxifen-resistant breast cancer using bioinformatics analysis , 2021, Translational cancer research.

[9]  J. Buján,et al.  The Regulatory Role of Mitochondrial MicroRNAs (MitomiRs) in Breast Cancer: Translational Implications Present and Future , 2020, Cancers.

[10]  Qian Su,et al.  SIRT3 is a downstream target of PPAR-α implicated in high glucose-induced cardiomyocyte injury in AC16 cells , 2020, Experimental and therapeutic medicine.

[11]  C. Kirwan,et al.  Does tamoxifen have a therapeutic role outside of breast cancer? A systematic review of the evidence. , 2020, Surgical oncology.

[12]  G. Karimi,et al.  The role of noncoding RNAs and sirtuins in cancer drug resistance. , 2020, European journal of pharmacology.

[13]  A. Mai,et al.  Sirtuin modulators: where are we now? A review of patents from 2015 to 2019 , 2020, Expert opinion on therapeutic patents.

[14]  Ying Xiang,et al.  The Dual Role of miR-186 in Cancers: Oncomir Battling With Tumor Suppressor miRNA , 2020, Frontiers in Oncology.

[15]  L. Csernoch,et al.  Impact of Sirtuin Enzymes on the Altered Metabolic Phenotype of Malignantly Transformed Cells , 2020, Frontiers in Oncology.

[16]  Wenyu Lin,et al.  LncRNAs regulate metabolism in cancer , 2020, International Journal on Biological Sciences.

[17]  S. Shukla,et al.  Hypoxia-induced changes in intragenic DNA methylation correlate with alternative splicing in breast cancer , 2020, Journal of Biosciences.

[18]  A. Ehinger,et al.  Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer , 2019, PloS one.

[19]  Haijun Li,et al.  Functions and mechanisms of miR-186 in human cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  M. Momeny,et al.  Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance , 2019, Oncogene.

[21]  Natalia Torrealba,et al.  Mitochondrial fragmentation, elevated mitochondrial superoxide and respiratory supercomplexes disassembly is connected with the tamoxifen-resistant phenotype of breast cancer cells. , 2019, Free radical biology & medicine.

[22]  K. Desai,et al.  Pathways to Endocrine Therapy Resistance in Breast Cancer , 2019, Front. Endocrinol..

[23]  Juan Sun,et al.  MicroRNA‐186 is associated with hypoxia‐inducible factor‐1α expression in chronic obstructive pulmonary disease , 2018, Molecular genetics & genomic medicine.

[24]  Ya-nan Zhang,et al.  miR‐186 inhibits proliferation, migration, and epithelial‐mesenchymal transition in breast cancer cells by targeting Twist1 , 2018, Journal of cellular biochemistry.

[25]  S. Thorpe,et al.  Tamoxifen mechanically reprograms the tumor microenvironment via HIF‐1A and reduces cancer cell survival , 2018, EMBO reports.

[26]  Yuanyuan Chen,et al.  Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[27]  Jonathan Hall,et al.  Noncoding RNAs in disease , 2018, FEBS letters.

[28]  L. Paavolainen,et al.  Association of tamoxifen resistance and lipid reprogramming in breast cancer , 2018, BMC Cancer.

[29]  X. Che,et al.  Suppression of Disheveled–Axin Domain Containing 1 (DIXDC1) by MicroRNA-186 Inhibits the Proliferation and Invasion of Retinoblastoma Cells , 2018, Journal of Molecular Neuroscience.

[30]  Guoxing Chen,et al.  LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis , 2017, Oncotarget.

[31]  Guang-hui Xu,et al.  Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer , 2017, Breast Cancer.

[32]  F. Sotgia,et al.  Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer , 2017, Oncotarget.

[33]  T. Chao,et al.  PPARs modulate cardiac metabolism and mitochondrial function in diabetes , 2017, Journal of Biomedical Science.

[34]  Matthew G. Vander Heiden,et al.  Altered metabolite levels in cancer: implications for tumour biology and cancer therapy , 2016, Nature Reviews Cancer.

[35]  Xin Tang,et al.  Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop , 2016, Tumor Biology.

[36]  Hsien-Da Huang,et al.  Long noncoding RNA TUG1 is downregulated in non-small cell lung cancer and can regulate CELF1 on binding to PRC2 , 2016, BMC Cancer.

[37]  V. Villegas,et al.  Tamoxifen Resistance: Emerging Molecular Targets , 2016, International journal of molecular sciences.

[38]  E. Rankin,et al.  Hypoxia: Signaling the Metastatic Cascade. , 2016, Trends in cancer.

[39]  Y. Wang,et al.  MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1α regulation , 2016, Oncogenesis.

[40]  J. Neuzil,et al.  MicroRNA in Metabolic Re-Programming and Their Role in Tumorigenesis , 2016, International journal of molecular sciences.

[41]  M. Dinger,et al.  Endogenous microRNA sponges: evidence and controversy , 2016, Nature Reviews Genetics.

[42]  D. Pang,et al.  Long non-coding RNA MVIH is associated with poor prognosis and malignant biological behavior in breast cancer , 2016, Tumor Biology.

[43]  J. Huh,et al.  Sirtuin 3 (SIRT3) maintains bone homeostasis by regulating AMPK-PGC-1β axis in mice , 2016, Scientific Reports.

[44]  V. Rani,et al.  Exploring miRNA based approaches in cancer diagnostics and therapeutics. , 2016, Critical reviews in oncology/hematology.

[45]  J. Ragoussis,et al.  Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer , 2015, Proceedings of the National Academy of Sciences.

[46]  Yongzhong Hou,et al.  PPARα regulates tumor progression, foe or friend? , 2015, European journal of pharmacology.

[47]  William J. Israelsen,et al.  Pyruvate kinase: Function, regulation and role in cancer. , 2015, Seminars in cell & developmental biology.

[48]  C. Klinge.  miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets , 2015, Molecular and Cellular Endocrinology.

[49]  Christian M. Metallo,et al.  Mitochondria as biosynthetic factories for cancer proliferation , 2015, Cancer & metabolism.

[50]  R. Kalluri,et al.  PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation to promote metastasis , 2014, Nature Cell Biology.

[51]  B. Grygiel-Górniak.  Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review , 2014, Nutrition Journal.

[52]  Xiuping Liu,et al.  Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells. , 2013, Biochemical pharmacology.

[53]  Aamir Ahmad,et al.  The Role of MicroRNAs in Breast Cancer Migration, Invasion and Metastasis , 2012, International journal of molecular sciences.

[54]  C. Prati,et al.  Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis , 2012, Arthritis Research & Therapy.

[55]  Paras Gupta,et al.  The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases , 2011, Journal of advanced pharmaceutical technology & research.

[56]  R. Clarke,et al.  Autophagy and endocrine resistance in breast cancer , 2011, Expert review of anticancer therapy.

[57]  L. Guarente,et al.  SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production , 2011, Oncogene.

[58]  J. Rinn,et al.  Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression , 2009, Proceedings of the National Academy of Sciences.

[59]  M. M. Coelho,et al.  Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. , 2007, European journal of pharmacology.

[60]  I. Hedenfalk,et al.  ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERα: a combination therapy potentially targeting hypoxic and dormant tumor cells , 2005, Oncogene.

[61]  Mitch Dowsett,et al.  Mechanisms of tamoxifen resistance. , 2004, Endocrine-related cancer.

[62]  G. Barish,et al.  PPARs and the complex journey to obesity , 2004, Nature Medicine.

[63]  W. Lee,et al.  Peroxisome proliferator–activated receptor α in the human breast cancer cell lines MCF‐7 and MDA‐MB‐231 , 2002, Molecular carcinogenesis.

[64]  C. Taylor,et al.  Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[66]  T. Lash,et al.  Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. , 2014, Future oncology.

[67]  J. Foekens,et al.  Tamoxifen Resistance in Breast Cancer , 2012, Drugs.